DARE DARE BIOSCIENCE INC Expansion Plans 8-K Filing 2024 - Clinical Study Plans Dare Bioscience announced plans for a Phase 3 clinical study of Sildenafil Cream, targeting female sexual arousal disorder, with submission to the FDA expected in early 2025 and study commencement aimed for mid-2025.Get access to all SEC 8-K filings of the DARE BIOSCIENCE INC